Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KIT exon17 |
| Therapy | Imatinib |
| Indication/Tumor Type | gastrointestinal stromal tumor |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KIT exon17 | gastrointestinal stromal tumor | resistant | Imatinib | Clinical Study - Meta-analysis | Actionable | In a meta-analysis, KIT exon 17 mutations were identified upon progression with Gleevec (imatinib) in 54.5% of patients with gastrointestinal stromal tumors harboring a primary KIT mutation (n=92) (PMID: 24369323). | 24369323 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (24369323) | Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. | Full reference... |